No, the FDA does not pre-approve cosmetics before they go to market in the United States — cleansing balms are regulated as cosmetics, not drugs, provided they make only cleansing or cosmetic claims (not therapeutic or SPF claims). However, compliance obligations under the Modernization of Cosmetics Regulation Act (MoCRA), signed into law in December 2022, are real and enforceable.
Under MoCRA, if your brand is the responsible party (the name and address on the label), you must register your manufacturing or processing facility with the FDA — the initial registration deadline for existing facilities has passed, so new entrants should register immediately upon beginning operations. You must also submit a product listing for each cosmetic product, including its ingredient list. These registrations are free and completed through FDA's Cosmetics Direct electronic portal.
You must also have a substantiation of safety on file — meaning documented evidence that your formula is safe under intended and reasonably foreseeable use conditions. Your manufacturer's stability data, a dermatologist review, and any allergy patch-test data all contribute to this file. You do not submit this to the FDA proactively; it must simply exist and be producible on request.
Serious adverse event reporting is now mandatory under MoCRA: if a consumer reports a serious adverse event (hospitalization, disfigurement, or similar) linked to your product, you must report it to the FDA within 15 business days.
What would push your cleansing balm into drug territory and trigger a much more rigorous pathway? Any SPF claim (even SPF 5), any claim to treat a skin condition (acne, rosacea, eczema), or any claim that the product alters the structure or function of the skin. Stick to cleansing, nourishing, and moisturizing language.
For EU or UK sales, requirements are stricter regardless of batch size: a Cosmetic Product Safety Report (CPSR) signed by a qualified toxicologist, notification on the CPNP (EU) or SCPN (UK) portal, a responsible person established in the relevant territory, and a product information file (PIF).
A common first-timer mistake is printing label copy without a compliance review and then needing to reprint an entire label run — often $300–$800 wasted. Have a regulatory consultant or your manufacturer's regulatory team review the label before you finalize artwork. AJ Cosmo Labs connects founders with formulators and compliance-aware contract manufacturers who flag these issues early in the project.
Read the full guide on Private Label Waterless Cleansing Balm Manufacturer Low MOQ →